Bausch + Lomb Corp
BLCO15.745USD
+0.745+4.97%
Fechamento 11/05, 16:00（ET）Cotações atrasadas em 15 min
5.58BValor de mercado
PerdaP/L TTM
Mais detalhes de Bausch + Lomb Corp Empresa
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Informações de Bausch + Lomb Corp
Código da empresaBLCO
Nome da EmpresaBausch + Lomb Corp
Data de listagemMay 06, 2022
CEOMr. Brenton L. (Brent) Saunders, J.D.
Número de funcionários13500
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 06
Endereço520 Applewood Crescent
CidadeVAUGHAN
Bolsa de valoresNYSE Consolidated
PaísCanada
Código postalL4K 4B4
Telefone19082552864
Sitehttps://ir.bausch.com/
Código da empresaBLCO
Data de listagemMay 06, 2022
CEOMr. Brenton L. (Brent) Saunders, J.D.
Executivos da empresa Bausch + Lomb Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+8.63%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+35.10%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
64.91K
+53.22%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Mr. Andrew J. Stewart
Mr. Andrew J. Stewart
President - Global Pharmaceuticals and International Consumer
President - Global Pharmaceuticals and International Consumer
--
--
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+8.63%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+35.10%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
64.91K
+53.22%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
OTC
482.00M
37.72%
Devices
472.00M
36.93%
Pharmaceuticals
260.00M
20.34%
Branded and other Generics
58.00M
4.54%
Other revenues
6.00M
0.47%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
OTC
482.00M
37.72%
Devices
472.00M
36.93%
Pharmaceuticals
260.00M
20.34%
Branded and other Generics
58.00M
4.54%
Other revenues
6.00M
0.47%
Distribuição de ações
Atualizado em: seg, 18 de ago
Atualizado em: seg, 18 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Bausch Health Companies Inc
87.68%
Icahn Associates Corporation
0.99%
Deutsche Bank Securities Inc.
0.96%
Alberta Investment Management Corporation
0.92%
D. E. Shaw & Co., L.P.
0.74%
Outro
8.71%
Investidores
Investidores
Proporção
Bausch Health Companies Inc
87.68%
Icahn Associates Corporation
0.99%
Deutsche Bank Securities Inc.
0.96%
Alberta Investment Management Corporation
0.92%
D. E. Shaw & Co., L.P.
0.74%
Outro
8.71%
Tipos de investidores
Investidores
Proporção
Corporation
87.68%
Hedge Fund
3.49%
Investment Advisor/Hedge Fund
3.31%
Research Firm
1.54%
Investment Advisor
1.52%
Sovereign Wealth Fund
0.92%
Individual Investor
0.48%
Pension Fund
0.25%
Family Office
0.24%
Outro
0.57%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
246
39.05M
11.03%
-24.81M
2025Q2
263
350.71M
99.08%
-19.09M
2025Q1
273
350.60M
99.12%
-19.40M
2024Q4
262
347.48M
98.58%
-23.77M
2024Q3
257
349.38M
99.14%
-19.72M
2024Q2
260
352.10M
99.92%
-21.43M
2024Q1
247
349.79M
99.91%
-25.18M
2023Q4
237
351.31M
100.35%
-21.66M
2023Q3
219
355.43M
101.52%
-16.80M
2023Q2
207
357.28M
102.06%
-12.23M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Bausch Health Companies Inc
310.45M
87.68%
--
--
Mar 24, 2025
Icahn Associates Corporation
3.50M
0.99%
--
--
Jun 30, 2025
Deutsche Bank Securities Inc.
3.41M
0.96%
-89.90K
-2.57%
Jun 30, 2025
Alberta Investment Management Corporation
3.27M
0.92%
+258.00K
+8.58%
Mar 31, 2025
D. E. Shaw & Co., L.P.
2.61M
0.74%
+728.68K
+38.79%
Jun 30, 2025
GoldenTree Asset Management, LP
2.58M
0.73%
+334.92K
+14.90%
Jun 30, 2025
Oaktree Capital Management, L.P.
2.52M
0.71%
+2.52M
--
Jun 30, 2025
Glenview Capital Management, LLC
1.55M
0.44%
+1.05M
+210.77%
Jun 30, 2025
Whitebox Advisors, L.L.C.
1.29M
0.36%
-331.23K
-20.41%
Jun 30, 2025
Nomura Securities Co., Ltd.
1.26M
0.35%
--
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
Ballast Small/Mid Cap ETF
1.45%
Invesco RAFI Developed Mkts ex-US SM ETF
0.03%
BNY Mellon US Small Cap Core Equity ETF
0.03%
Schwab Fundamental International Small Equity ETF
0%
Goldman Sachs MarketBeta US 1000 Equity ETF
0%
Invesco Zacks Mid-Cap ETF
0%
QRAFT AI-Enhanced US Large Cap ETF
0%
AltShares Event-Driven ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
BNY Mellon US Mid Cap Core Equity ETF
0%
Ver Mais
Ballast Small/Mid Cap ETF
Proporção1.45%
Invesco RAFI Developed Mkts ex-US SM ETF
Proporção0.03%
BNY Mellon US Small Cap Core Equity ETF
Proporção0.03%
Schwab Fundamental International Small Equity ETF
Proporção0%
Goldman Sachs MarketBeta US 1000 Equity ETF
Proporção0%
Invesco Zacks Mid-Cap ETF
Proporção0%
QRAFT AI-Enhanced US Large Cap ETF
Proporção0%
AltShares Event-Driven ETF
Proporção0%
DFA Dimensional International Core Equity 2 ETF
Proporção0%
BNY Mellon US Mid Cap Core Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
